Navigation Links
Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
Date:4/29/2008

harma AG; changes in the company's business plan or objectives; the ability of the company to attract and retain qualified personnel; competition in general; and the company's ability to obtain, maintain and enforce patent and other intellectual property protection for its product candidates and its discoveries. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" in the company's annual report on Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission (SEC) and other filings that the company makes with the SEC.

All forward-looking statements reflect the company's expectations only as of the date of this release and should not be relied upon as reflecting the company's views, expectations or beliefs at any date subsequent to the date of this release. Idenix anticipates that subsequent events and developments may cause these views, expectations and beliefs to change. However, while Idenix may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

IDENIX PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(IN THOUSANDS, EXCEPT PER SHARE DATA)

(UNAUDITED)

Three Months Ended

March 31,

2008 2007

Revenues:

Collaboration revenue - related party $2,031 $24,351

Other revenue 13 455

Total revenues 2,044 24,806

Operating expenses (1):

Cost of sales 395 70

Research a
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
2. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
3. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
4. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
5. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
6. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
7. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
8. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
9. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
10. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
11. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire-iReach/ -- SAM Medical Products ... for the SAM Junctional Tourniquet.  ... SAM Medical Products announced today that it has ... address a potential issue with a clip used ... Axilla application of the SAM Junctional Tourniquet (SJT).  ...
(Date:8/29/2014)... , Aug. 29, 2014   Mast Therapeutics, ... company, announced today that Santosh Vetticaden, Chief Medical ... the Company, for personal reasons, in mid-September.  ... Officer of Aires Pharmaceuticals, which Mast acquired earlier ... as the Company,s interim Chief Medical Officer.  Dr. ...
(Date:8/29/2014)... Utah , Aug. 29, 2014  BC Technical, ... has acquired Polaris Medical Imaging, a leader in sales, ... This strategic acquisition allows BC Technical to continue to ... specifically within MR and CT modalities. ... service," said Mark Alvarez , president and CEO ...
Breaking Medicine Technology:SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4BC Technical Acquires Polaris Medical Imaging 2
... Pharmacyclics, Inc.,(Nasdaq: PCYC ) today announced ... dose-escalation study to evaluate the safety and tolerability of ... or Btk,as a potential treatment for patients with relapsed ... the first Btk selective inhibitor to,be tested in humans, ...
... MicroRNA-based Molecular Diagnostics to Mark Prometheus, Entry into ... and Development Funding plus Future RoyaltiesSAN DIEGO, PHILADELPHIA ... Inc., a specialty pharmaceutical and diagnostic company, and ... an innovative molecular diagnostic company, today announced the ...
Cached Medicine Technology:Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 2Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 3Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 4Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 5Prometheus and Rosetta Genomics Announce License and Collaboration Agreement 2Prometheus and Rosetta Genomics Announce License and Collaboration Agreement 3Prometheus and Rosetta Genomics Announce License and Collaboration Agreement 4Prometheus and Rosetta Genomics Announce License and Collaboration Agreement 5Prometheus and Rosetta Genomics Announce License and Collaboration Agreement 6
(Date:8/31/2014)... 31, 2014 To make it easy ... they can trust, NutriGold is shipping complimentary samples of ... has been set up to make taking advantage of ... According to Priya Khan, Director of Research and Development ... one of our products, they are entrusting us with ...
(Date:8/31/2014)... Rockville, MD (PRWEB) August 31, 2014 ... electronic health records (EHR) software firm that focuses ... overall practice success found a congruent commitment with ... In Sports . , “We create an environment ... and effortlessly, allowing more time with patients,” says ...
(Date:8/31/2014)... Richmond, CA (PRWEB) August 31, 2014 ... program of the California State Library, celebrates 30 ... and their families. Since its inception, California’s Library ... a million Californians learn to read and write. ... this volunteer-based program, the state is launching a ...
(Date:8/31/2014)... Wine only protects against cardiovascular disease (CVD) in people ... Veritas (IVV) study presented at ESC Congress today by ... Taborsky said: "This is the first randomised trial comparing ... of atherosclerosis (1) in people at mild to moderate ... was only protective in people who exercised. Red and ...
(Date:8/30/2014)... A retrievable and repositionable transcatheter aortic valve is ... according to research presented at ESC Congress 2014 ... direct flow medical (DFM) transcatheter aortic valve has ... the potential to improve transcatheter aortic valve implantation ... , Dr Pyxaras said: "TAVI is well established ...
Breaking Medicine News(10 mins):Health News:Whole-food Supplement Samples Now Offered by NutriGold 2Health News:Whole-food Supplement Samples Now Offered by NutriGold 3Health News:Powerhouse EHR, Future Health, Announces Gold Sponsorship of POWERPlay in Sports National Tour 2Health News:Powerhouse EHR, Future Health, Announces Gold Sponsorship of POWERPlay in Sports National Tour 3Health News:Powerhouse EHR, Future Health, Announces Gold Sponsorship of POWERPlay in Sports National Tour 4Health News:California Library Literacy Services Celebrates 30th Anniversary 2Health News:California Library Literacy Services Celebrates 30th Anniversary 3Health News:Wine only protects against CVD in people who exercise 2Health News:Retrievable transcatheter aortic valve effective and safe in real world setting 2
... Reporter , MONDAY, May 28 (HealthDay News) -- Updated ... good news for those at risk of osteoporosis, but ... other chronic diseases. While estrogen-only and estrogen-plus-progestin formulations ... for stroke and other conditions including gallbladder disease, according ...
... study suggests that aspirin and other similar painkillers may ... CANCER , a peer-reviewed journal of the American ... may be added to the benefits of these commonly ... anti-inflammatory drugs, or NSAIDs, which include aspirin, ibuprofen, and ...
... Reporter , MONDAY, May 28 (HealthDay News) -- Sensory ... increasingly used by occupational therapists to treat children with ... organization says there isn,t much evidence that such therapies ... the potential of sensory therapies -- it,s a ripe ...
... -- Picnics, parades and cookouts are as much a part ... war veterans. But, before tucking into that leafy, green ... vegetables can become contaminated with harmful pathogens that cause food ... listeria and norovirus, according to the Academy of ...
... -- Boosting students, levels of physical education improves their ... followed more than 200 schoolchildren, starting from first through ... to an intervention group that received physical education five ... such as balance and coordination. The other children were ...
... , FRIDAY, May 25 (HealthDay News) -- People ... colitis, may be at increased risk for flare-ups when ... or mountain climbing, a new study suggests. This ... involves the small intestine) or ulcerative colitis (which typically ...
Cached Medicine News:Health News:HRT Update: Therapy May Reduce Fractures, Boost Some Risks 2Health News:HRT Update: Therapy May Reduce Fractures, Boost Some Risks 3Health News:Commonly used painkillers may protect against skin cancer 2Health News:Doubt Cast on Usefulness of 'Sensory' Therapies for Autism 2Health News:Doubt Cast on Usefulness of 'Sensory' Therapies for Autism 3Health News:Keep Food Safety in Mind This Memorial Day Weekend 2Health News:Travel to High Altitudes Tied to Crohn's, Colitis Flare-Ups 2
... Monitor (PCM) and Central Station provide an ... extends the cardiac cath or electrophysiology lab ... and/or EP procedures, providing both physiomonitoring parameters ... either standalone or on its own network. ...
For the critical care environment, telemetry, emergency room and other monitoring areas....
DS 7600 Central Station...
... Gemini Family of infusion pumps ... a collective series of administration ... line offers a wide variety ... sets, each featuring the patented ...
Medicine Products: